Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay.

Sofat R, Mangione PP, Gallimore JR, Hakobyan S, Hughes TR, Shah T, Goodship T, D'Aiuto F, Langenberg C, Wareham N, Morgan BP, Pepys MB, Hingorani AD.

J Immunol Methods. 2013 Apr 30;390(1-2):63-73. doi: 10.1016/j.jim.2013.01.009. Epub 2013 Jan 30.

PMID:
23376722
2.

Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use.

Pepys MB, Gallimore JR, Lloyd J, Li Z, Graham D, Taylor GW, Ellmerich S, Mangione PP, Tennent GA, Hutchinson WL, Millar DJ, Bennett G, More J, Evans D, Mistry Y, Poole S, Hawkins PN.

J Immunol Methods. 2012 Oct 31;384(1-2):92-102. doi: 10.1016/j.jim.2012.07.013. Epub 2012 Jul 31.

3.

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB.

Nature. 2010 Nov 4;468(7320):93-7. doi: 10.1038/nature09494. Epub 2010 Oct 20.

5.

Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.

Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB.

Br J Haematol. 2010 Mar;148(5):760-7. doi: 10.1111/j.1365-2141.2009.08036.x. Epub 2010 Jan 8.

PMID:
20064157
6.

Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.

Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7619-23. doi: 10.1073/pnas.0902640106. Epub 2009 Apr 16.

7.

Serum amyloid A, C-reactive protein, and retinal microvascular changes in hypertensive diabetic and nondiabetic individuals: an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy.

Stettler C, Witt N, Tapp RJ, Thom S, Allemann S, Tillin T, Stanton A, O'Brien E, Poulter N, Gallimore JR, Hughes AD, Chaturvedi N.

Diabetes Care. 2009 Jun;32(6):1098-100. doi: 10.2337/dc08-2137. Epub 2009 Feb 24.

8.

Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice.

Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, Sabin CA, Dhillon AP, Pepys MB.

Atherosclerosis. 2008 Jan;196(1):248-55. Epub 2007 Jun 22.

PMID:
17588586
9.

Natural history and outcome in systemic AA amyloidosis.

Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN.

N Engl J Med. 2007 Jun 7;356(23):2361-71.

10.

Normal circulating serum amyloid P component concentration in systemic sclerosis.

Tennent GA, Dziadzio M, Triantafillidou E, Davies P, Gallimore JR, Denton CP, Pepys MB.

Arthritis Rheum. 2007 Jun;56(6):2013-7.

11.

Is leptin an important physiological regulator of CRP?

Hutchinson WL, Coll AP, Gallimore JR, Tennent GA, Pepys MB.

Nat Med. 2007 Jan;13(1):17-8; author reply 19-21. No abstract available.

PMID:
17206123
12.

Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations.

Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, Roberts PF, Woo P, Grattan CE, Hawkins PN.

Arch Dermatol. 2006 Dec;142(12):1591-7.

PMID:
17178985
13.

Targeting C-reactive protein for the treatment of cardiovascular disease.

Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP.

Nature. 2006 Apr 27;440(7088):1217-21.

PMID:
16642000
14.

Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations.

Lachmann HJ, Sengül B, Yavuzşen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soytürk M, Akar S, Tunca M, Hawkins PN.

Rheumatology (Oxford). 2006 Jun;45(6):746-50. Epub 2006 Jan 10.

PMID:
16403826
15.

Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself.

Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, Sabin CA, Zychlinsky A, de Diego J.

Circ Res. 2005 Nov 25;97(11):e97-103. Epub 2005 Oct 27.

16.

Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice.

Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8309-14. Epub 2005 May 26.

17.

Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability.

Clapp BR, Hirschfield GM, Storry C, Gallimore JR, Stidwill RP, Singer M, Deanfield JE, MacAllister RJ, Pepys MB, Vallance P, Hingorani AD.

Circulation. 2005 Mar 29;111(12):1530-6.

PMID:
15795363
18.

The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial.

Tunca M, Akar S, Soytürk M, Kirkali G, Resmi H, Akhunlar H, Gönen O, Gallimore JR, Hawkins PN, Tankurt E.

Clin Exp Rheumatol. 2004 Jul-Aug;22(4 Suppl 34):S37-40.

PMID:
15515782
19.

Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting.

Gomma AH, Hirschfield GM, Gallimore JR Jr, Lowe GD, Pepys MB, Fox KM.

Am Heart J. 2004 Jun;147(6):1071-7.

PMID:
15199358
20.

Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences.

Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Gallimore JR, Pepys MB, Campbell LV.

Circulation. 2004 Jun 22;109(24):3022-8. Epub 2004 Jun 7.

PMID:
15184288
21.

Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins.

MacGregor AJ, Gallimore JR, Spector TD, Pepys MB.

Clin Chem. 2004 Jan;50(1):130-4. Epub 2003 Nov 18.

22.

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.

Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN.

Nature. 2002 May 16;417(6886):254-9.

PMID:
12015594
23.

C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites.

Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR, Pepys MB, Kooner JS.

Circulation. 2001 Jul 10;104(2):145-50.

PMID:
11447077
24.

Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen.

Noursadeghi M, Bickerstaff MC, Gallimore JR, Herbert J, Cohen J, Pepys MB.

Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14584-9.

25.

Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.

Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB.

BMJ. 2000 Jul 22;321(7255):199-204.

26.

Enhanced inflammatory response in patients with preinfarction unstable angina.

Liuzzo G, Biasucci LM, Gallimore JR, Caligiuri G, Buffon A, Rebuzzi AG, Pepys MB, Maseri A.

J Am Coll Cardiol. 1999 Nov 15;34(6):1696-703.

27.

Risk factors for coronary heart disease and acute-phase proteins. A population-based study.

Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB.

Eur Heart J. 1999 Jul;20(13):954-9.

PMID:
10361047
28.

Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina.

Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, Altamura S, Ciliberto G, Rebuzzi AG, Crea F, Pepys MB, Maseri A.

Circulation. 1998 Dec 1;98(22):2370-6.

PMID:
9832480
29.

Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris.

Rebuzzi AG, Quaranta G, Liuzzo G, Caligiuri G, Lanza GA, Gallimore JR, Grillo RL, Cianflone D, Biasucci LM, Maseri A.

Am J Cardiol. 1998 Sep 15;82(6):715-9.

PMID:
9761079
30.

The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study.

Poole S, Walker D, Gaines Das RE, Gallimore JR, Pepys MB.

J Immunol Methods. 1998 May 1;214(1-2):1-10.

PMID:
9692853
31.

Rapid automated high sensitivity enzyme immunoassay of C-reactive protein.

Wilkins J, Gallimore JR, Moore EG, Pepys MB.

Clin Chem. 1998 Jun;44(6 Pt 1):1358-61. No abstract available.

32.

Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses.

Ashton AW, Boehm MK, Gallimore JR, Pepys MB, Perkins SJ.

J Mol Biol. 1997 Sep 26;272(3):408-22.

PMID:
9325100
33.

Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease.

Spector TD, Hart DJ, Nandra D, Doyle DV, Mackillop N, Gallimore JR, Pepys MB.

Arthritis Rheum. 1997 Apr;40(4):723-7.

PMID:
9125256
34.
35.

Serum amyloid A protein is a clinically useful indicator of acute renal allograft rejection.

Hartmann A, Eide TC, Fauchald P, Bentdal O, Herbert J, Gallimore JR, Pepys MB.

Nephrol Dial Transplant. 1997 Jan;12(1):161-6.

PMID:
9027793
36.

Plasma protein acute-phase response in unstable angina is not induced by ischemic injury.

Liuzzo G, Biasucci LM, Rebuzzi AG, Gallimore JR, Caligiuri G, Lanza GA, Quaranta G, Monaco C, Pepys MB, Maseri A.

Circulation. 1996 Nov 15;94(10):2373-80.

PMID:
8921776
37.

The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.

Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A.

N Engl J Med. 1994 Aug 18;331(7):417-24.

38.

Rapid automated enzyme immunoassay of serum amyloid A.

Wilkins J, Gallimore JR, Tennent GA, Hawkins PN, Limburg PC, van Rijswijk MH, Moore EG, Pepys MB.

Clin Chem. 1994 Jul;40(7 Pt 1):1284-90.

39.

Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease.

Hawkins PN, Rossor MN, Gallimore JR, Miller B, Moore EG, Pepys MB.

Biochem Biophys Res Commun. 1994 Jun 15;201(2):722-6.

PMID:
7516157
40.

Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.

Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL, Hawkins PN, Nelson SR, Gallimore JR, Herbert J, et al.

Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5602-6.

41.

Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease.

Stuart J, Stone PC, Akinola NO, Gallimore JR, Pepys MB.

J Clin Pathol. 1994 Feb;47(2):166-9.

42.

The International Standard for Thyroxine Binding Globulin.

Bristow AF, Gaines-Das RE, Buttress N, Gallimore JR, Tennent GA, Pepys MB.

Clin Endocrinol (Oxf). 1993 Apr;38(4):361-6.

PMID:
8319367

Supplemental Content

Loading ...
Support Center